Dabrafenib mesylate
| Dabrafenib mesylate | |
|---|---|
| Term | Dabrafenib mesylate |
| Short definition | Dabrafenib mesylate - (pronounced) (duh-BRA-feh-nib MEH-zih-layt) A drug used alone or with trametinib to treat certain types of anaplastic thyroid cancer, non-small cell lung cancer, melanoma, and other solid tumors that have a specific mutation (change) in the skinBRAFGen. It is also being studied in the treatment of other types of cancer. |
| Type | Cancer terms |
| Specialty | Oncology |
| Language | English |
| Source | NCI |
| Comments | |
Dabrafenib mesylate - (pronounced) (duh-BRA-feh-nib MEH-zih-layt) A drug used alone or with trametinib to treat certain types of anaplastic thyroid cancer, non-small cell lung cancer, melanoma, and other solid tumors that have a specific mutation (change) in the skinBRAFGen. It is also being studied in the treatment of other types of cancer. Dabrafenib mesylate blocks certain proteins made by the mutationBRAFGene that can help stop cancer cells from growing. It's a kind of kinase inhibitor. Also called Tafinlar
External links
- Medical encyclopedia article on Dabrafenib mesylate
- Wikipedia's article - Dabrafenib mesylate
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski